These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 7977225

  • 1. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.
    Steinhart AH, Hemphill D, Greenberg GR.
    Am J Gastroenterol; 1994 Dec; 89(12):2116-24. PubMed ID: 7977225
    [Abstract] [Full Text] [Related]

  • 2. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB.
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis.
    Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d'Albasio G, De Simone G, Martini N.
    Am J Gastroenterol; 1994 May; 89(5):692-8. PubMed ID: 8172139
    [Abstract] [Full Text] [Related]

  • 4. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG, Sandborn WJ.
    Rev Gastroenterol Disord; 2002 May; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [Abstract] [Full Text] [Related]

  • 5. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
    Sandborn WJ, Feagan BG, Lichtenstein GR.
    Aliment Pharmacol Ther; 2007 Oct 01; 26(7):987-1003. PubMed ID: 17877506
    [Abstract] [Full Text] [Related]

  • 6. Current treatment for prevention of relapse and recurrence in Crohn's disease.
    Prantera C, Scribano ML.
    Ital J Gastroenterol Hepatol; 1999 Oct 01; 31(6):515-8. PubMed ID: 10575572
    [Abstract] [Full Text] [Related]

  • 7. The role of mesalazine in Crohn's disease.
    Hanauer SB.
    Scand J Gastroenterol Suppl; 1990 Oct 01; 172():56-9. PubMed ID: 1972296
    [Abstract] [Full Text] [Related]

  • 8. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH, Munck LK.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 01; 4(3):160-70. PubMed ID: 17339853
    [Abstract] [Full Text] [Related]

  • 9. A meta-analysis of antimycobacterial therapy for Crohn's disease.
    Borgaonkar MR, MacIntosh DG, Fardy JM.
    Am J Gastroenterol; 2000 Mar 01; 95(3):725-9. PubMed ID: 10710065
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE, Schraa CC.
    Pharmacotherapy; 1994 Mar 01; 14(4):385-98. PubMed ID: 7937276
    [Abstract] [Full Text] [Related]

  • 12. Maintenance treatment for Crohn's disease: has the time arrived?
    Goldstein F.
    Am J Gastroenterol; 1992 May 01; 87(5):551-6. PubMed ID: 1350706
    [No Abstract] [Full Text] [Related]

  • 13. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.
    Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H.
    Gastroenterology; 1984 Feb 01; 86(2):249-66. PubMed ID: 6140202
    [Abstract] [Full Text] [Related]

  • 14. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE, Hanauer SB.
    Gastroenterol Clin North Am; 2004 Jun 01; 33(2):303-17, ix-x. PubMed ID: 15177540
    [Abstract] [Full Text] [Related]

  • 15. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A, Griga T, May B.
    Hepatogastroenterology; 1999 Jun 01; 46(30):3124-35. PubMed ID: 10626173
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U, Maier K, Fischer C, Heinkel K.
    N Engl J Med; 1980 Dec 25; 303(26):1499-502. PubMed ID: 6107853
    [Abstract] [Full Text] [Related]

  • 17. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
    Uittenbogaart SB, Klemt-Kropp M.
    Ned Tijdschr Geneeskd; 2011 Dec 25; 155(48):A3842. PubMed ID: 22152414
    [Abstract] [Full Text] [Related]

  • 18. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H, Munakata A, Yoshida Y.
    J Gastroenterol; 1995 Nov 25; 30 Suppl 8():115-7. PubMed ID: 8563870
    [Abstract] [Full Text] [Related]

  • 19. Favorable effects of sulfasalazine on small bowel Crohn's disease: a long-term study.
    Goldstein F, Farquhar S, Thornton JJ, Abramson J.
    Am J Gastroenterol; 1987 Sep 25; 82(9):848-53. PubMed ID: 2888305
    [Abstract] [Full Text] [Related]

  • 20. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
    Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY.
    Gastroenterol Clin Biol; 2009 Jan 25; 33(1 Pt 1):31-40. PubMed ID: 19118966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.